Welcome to our dedicated page for Rapid Micro Biosystems news (Ticker: RPID), a resource for investors and traders seeking the latest updates and insights on Rapid Micro Biosystems stock.
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) is a life sciences technology company that regularly issues news and updates related to its automated microbial quality control (MQC) solutions for pharmaceutical and biopharmaceutical manufacturing. Company press releases focus on the performance and adoption of its flagship Growth Direct system, which automates and modernizes manual MQC testing workflows used in large and complex pharmaceutical manufacturing operations across the globe.
News for RPID often covers quarterly and annual financial results, including product revenue, service revenue, and recurring revenue from consumables and annual service contracts. The company highlights metrics such as system placements, customer system validations, recurring revenue growth, and record consumable revenue. Updates have also described record multi-system orders from an existing Top 20 global biopharma customer to automate a global manufacturing network across North America, Europe, and Asia Pacific.
Investors and industry followers can also expect announcements about capital structure and financing, such as the disclosed five-year, $45 million term loan facility with Trinity Capital Inc., as well as news on the company’s financial position and outlook. Additional news items include participation in major healthcare and investor conferences, including the J.P. Morgan Healthcare Conference, the Stifel Healthcare Conference, and the H.C. Wainwright Global Investment Conference, where management presents and engages with analysts and investors.
This RPID news page on Stock Titan aggregates these types of updates so readers can quickly review earnings announcements, financing developments, system placement milestones, and conference participation related to Rapid Micro Biosystems. Users interested in the evolution of automated microbial quality control in biopharma manufacturing can monitor this feed for the company’s latest publicly released information.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) announced the exercise of an over-allotment option from its initial public offering, resulting in the sale of 1,086,604 additional shares at $20.00 each, generating gross proceeds of $21.7 million. This transaction closed on August 4, 2021. The offering was managed by J.P. Morgan, Morgan Stanley, Cowen, and Stifel. The registration statement for this offering became effective on July 14, 2021, and details can be accessed through the designated underwriters.
Rapid Micro Biosystems (Nasdaq: RPID) has appointed Melinda Litherland to its board of directors as of June 2021. Litherland, a CPA with over 30 years in audit experience, brings significant expertise in the Technology and Life Sciences sectors from her tenure at Deloitte. The company aims to leverage her financial acumen to address complex accounting challenges while pursuing its goal of becoming a leader in microbial quality control. Rapid Micro specializes in automation solutions for the healthcare industry, including the innovative Growth Direct® platform, enhancing operational efficiency and compliance in pharmaceutical manufacturing.
Rapid Micro Biosystems announced the pricing of its initial public offering (IPO) of 7,920,000 shares of Class A common stock at $20.00 per share, aiming to raise $158.4 million before expenses. The shares will trade on the Nasdaq under the symbol RPID starting July 15, 2021, with the offering expected to close on July 19, 2021. Underwriters have a 30-day option to purchase an additional 1,188,000 shares. The company focuses on automation solutions for healthcare product manufacturing.